Abd El-Ghany Hoda M, El Ashry Mona S, Abdellateif Mona S, Rabea Ahmed, Sultan Nada, Abd El Dayem Omnia Y
Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo 11976, Al Qāhirah, Egypt.
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo 11976, Al Qāhirah, Egypt.
World J Exp Med. 2025 Mar 20;15(1):99516. doi: 10.5493/wjem.v15.i1.99516.
Acute myeloid leukemia (AML) is a complicated disease with uncontrolled hematopoietic precursor proliferation induced by various genetic alterations. Runt-related transcription factor-1 () is commonly disrupted by chromosomal translocations in hematological malignancies.
To characterize gene rearrangements and copy number variations in newly diagnosed adult AML patients, with an emphasis on the impact of clinical and laboratory features on the outcome.
Fluorescence in situ hybridization was used to test gene alterations in 77 newly diagnosed adult AML cases. , , , and mutations were tested by PCR. Prognostic clinical and laboratory findings were studied in relation to alterations.
abnormalities were detected by fluorescence in situ hybridization in 41.6% of patients: 20.8% had translocations, 22.1% had amplification, and 5.2% had deletion. Translocations prevailed in AML-M2 ( = 0.019) with a positive expression of myeloperoxidase ( = 0.031), whereas deletions dominated in M4 and M5 subtypes ( = 0.008) with a positive association with CD64 expression ( = 0.05). The modal chromosomal number was higher in cases having amplifications ( = 0.007) and lower in those with deletions ( = 0.008). abnormalities were associated with complex karyotypes ( < 0.001) and were mutually exclusive of mutations. After 44 months of follow-up, abnormalities affected neither patients' response to treatment nor overall survival.
abnormalities were mutually exclusive of mutations. abnormalities affected neither patients' response to treatment nor overall survival.
急性髓系白血病(AML)是一种复杂的疾病,由各种基因改变导致造血前体细胞增殖失控。 runt相关转录因子1(RUNX)在血液系统恶性肿瘤中常因染色体易位而被破坏。
对新诊断的成年AML患者的RUNX基因重排和拷贝数变异进行特征分析,重点关注临床和实验室特征对预后的影响。
采用荧光原位杂交技术检测77例新诊断成年AML病例的RUNX基因改变。通过聚合酶链反应检测NRAS、KRAS、FLT3和NPM1突变。研究预后相关的临床和实验室结果与RUNX改变的关系。
荧光原位杂交检测发现41.6%的患者存在RUNX异常:20.8%有易位,22.1%有扩增,5.2%有缺失。易位在髓过氧化物酶阳性的AML-M2中占主导(P = 0.019),而缺失在M4和M5亚型中占主导(P = 0.008),且与CD64表达呈正相关(P = 0.05)。有扩增的病例中染色体众数较高(P = 0.007),有缺失的病例中染色体众数较低(P = 0.008)。RUNX异常与复杂核型相关(P < 0.001),且与NRAS突变相互排斥。随访44个月后,RUNX异常既不影响患者的治疗反应,也不影响总生存期。
RUNX异常与NRAS突变相互排斥。RUNX异常既不影响患者的治疗反应,也不影响总生存期。